David Newble
Executive Advisor
David joined Ampersand as an Executive Advisor in 2025, bringing over 20 years of leadership experience in the life sciences tools, automation, and services sectors. He currently serves as Chairman of Cresset, a UK-based provider of computational chemistry software for drug discovery. Previously, David was CEO of SPT Labtech, where he led the company through a period of significant global expansion and innovation in laboratory automation. Prior to that, he served as CEO of TAP Biosystems, where he oversaw the development and commercialization of the Ambr® bioreactor platform and guided the company through its successful acquisition by Sartorius. David has also held senior financial roles at BTG and was the founder of Fluidic Sciences, a company focused on protein analysis. He holds a degree in Physics from Queen Mary University of London and is a qualified Chartered Accountant (ACA).